Core Insights - The article highlights the successful international approval of Liraglutide injection by Tonghua Dongbao Pharmaceutical Co., Ltd. in Peru, marking a significant milestone in the company's global expansion strategy in the GLP-1 product category [4] - Liraglutide, a GLP-1 analog, is recognized for its efficacy in improving blood sugar levels, cardiovascular protection, and weight loss, gaining global acceptance [4] Market Growth and Strategy - The International Diabetes Federation (IDF) projects that the number of adults aged 20-79 with diabetes will reach 589 million in 2024, with a prevalence rate of 11.1%, and is expected to rise to 853 million by 2050, indicating a growing market for diabetes treatments [6] - The company, in collaboration with Sinovac Biotech, is targeting emerging markets with high diabetes prevalence, covering 17 countries across Latin America, the Middle East and North Africa, Southeast Asia, and South Africa [6] Product Development and Internationalization - The company has achieved significant progress in international registrations for multiple products, including Liraglutide and insulin formulations, with approvals in Indonesia, Uzbekistan, and other emerging markets [7] - The internationalization strategy is set to accelerate, aiming to expand overseas sales and provide accessible diabetes treatment options to a broader patient base [7]